Merck (NYSE:MRK) announced that a group of independent advisors to the U.S. CDC unanimously voted to recommend its newly approved pneumonia vaccine, Capvaxive, for adults aged 65 years and older.

Merck's shot, called Capvaxive, specifically protects against 21 strains of that bacteria to prevent a severe form of pneumococcal disease that can spread to other parts of the body and lead to ...

FDA approval of Merck’s new pneumococcal vaccine, Capvaxive, tees up a new challenge to one of Pfizer’s most important products.

With Capvaxive, MSD (known as Merck & Co in the US and Canada) is aiming to carve out a niche in the over-50s, positioning it as the go-to vaccine used to prevent invasive pneumococcal disease ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

In recent months, Merck has made notable strides in expanding its product offerings. The company received FDA approval for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine (PCV) for adults, ...